1 Werewolf Therapeutics Inc Receivables Turnover Ratio (HOWL), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Werewolf Therapeutics Inc   (NASDAQ: HOWL)
 

Werewolf Therapeutics Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


According to Werewolf Therapeutics Inc Balance Sheet, in the second quarter 2026, company has not reported any Accounts receivable.
See Werewolf Therapeutics Inc Balance Sheet

If we take a look into Healthcare sector Werewolf Therapeutics Inc achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Werewolf Therapeutics Inc Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HOWL Receivables Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Receivable Change - - - - -
Y / Y Revenue Change - - - - -
Receivable Turnover Ratio (TTM) - - - - -
HOWL's Total Ranking # # # # #
Accounts Receivable average collection period days - - - - -
Seq. Receivable Change - - - - -
Seq. Revenue Change - - - - -


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #

Receivable Turnover Ratio Statistics
High Average Low
0 0 0
 




  News about Werewolf Therapeutics Inc Receivables Turnover Ratios

Breakthrough in Cancer Immunotherapy Werewolf Therapeutics Reports Promising Phase 1 Clinical Data for Tumor-Act...

Werewolf Therapeutics Showcases Promising Data for WTX-330 at SITC Annual MeetingIn a significant contribution to cancer immunotherapy, Werewolf Therapeutics has presented both preclinical and clinical data on its investigational tumor-activated interleukin-12 (IL-12) prodrug, WTX-330, at the recently concluded Society for Immunotherapy of Cancers (SITC) 39th Annual Meeting. This presentation highlighted interim data from a Phase 1 clinical trial that showcases the potential of WTX-330 as a novel therapeutic agent with a favorable tolerability profile and promising efficacy signals. Unlocking the Potential of IL-12 TherapyIL-12 is a key cytokine involved in the regulation of immune responses, particularly in the activation of T-cells and natural killer (NK) cells, vital components of the body’s immune defense against tumors. However, conventional use of IL-12 in therapeutic applications has been hampered by systemic toxicity and limited tolerability. Werewolf Therapeutics has taken a revolutionary approach by developing WTX-330, a prodrug designed to activate IL-12 specifically within the tumor microenvironment. This innovative design aims to enhance the localized efficacy of IL-12 while minimizing systemic exposure and adverse effects. The preclinical data presented by Werewolf Therapeutics underscores the differentiated mechanism of action of WTX-330, demonstrating its potential to stimulate robust anti-tumor immune responses with an improved safety profile.


HOWL Company Profile • Back to HOWL Efficiency Comparisons • Compare HOWL Receivables Turnover Ratio to its Competitors

Financial Statements
Werewolf Therapeutics Inc 's Accounts Receivable $ 0 Millions Visit HOWL's Balance sheet
Werewolf Therapeutics Inc 's Sales TTM $ 21 Millions Visit HOWL's Income Statement
Sources of HOWL's Revenues Visit HOWL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
HOWL's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
HOWL's Growth Rates HOWL's Roa HOWL's Inventory Turnover Ratio HOWL's Dividend Comparisons
HOWL's Profitability Ratios HOWL's Roi HOWL's Asset Turnover Ratio HOWL's Dividend Growth
HOWL's Valuation Ratios HOWL's Roe HOWL's Financial Strength Ratios HOWL's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026

Date modified: 2026-08-30T20:41:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.